Abstract

Protocol of Blood Serum Eye Drops

Author(s): Katsakoulas Ioannis, Lougovoi Claudia, Paraskevopoulou Penelope, Vougioukas Nikolaos

Issue: May/Jun 2015 - Volume 19, Number 3

Page(s): 252-260

Download in electronic PDF format for $75
  • Protocol of Blood Serum Eye Drops Page 1
  • Protocol of Blood Serum Eye Drops Page 2
  • Protocol of Blood Serum Eye Drops Page 3
  • Protocol of Blood Serum Eye Drops Page 4
  • Protocol of Blood Serum Eye Drops Page 5
  • Protocol of Blood Serum Eye Drops Page 6
  • Protocol of Blood Serum Eye Drops Page 7
  • Protocol of Blood Serum Eye Drops Page 8
  • Protocol of Blood Serum Eye Drops Page 9

Abstract

Keratoconjunctivitis sicca is one of the most frequent diagnoses for seeking eye care. Accumulated evidence over the past three decades has revealed a significant contribution of several molecules contained in tears at the homeostasis of the epithelium of the ocular surface. Therefore, autologous blood serum in the form of eye drops can provide substantial help in the management of keratoconjunctivitis sicca. Also making this a favorable treatment for keratoconjunctivitis sicca is the fact that this approach has become an insurance-covered benefit in some countries. This report demonstrates a formulation of blood serum eye drops with the purpose of providing an alternative to the marked absence of a universally established protocol. Exclusion criteria, equipment, preservation, dosage, duration, and guidelines for patients are described. Also included are details on the treatment of one representative embodiment. All (pre-/post-)analytical considerations and the total cost are addressed. Outcome measures such as Schirmer’ s test, break up time, and Ocular Surface Disease Index score are recorded before treatment, at 1 and 2 months, ideally as monotherapy with 100% serum q.i.d. Blood serum isolated under aseptic conditions maintained throughout is delivered as a ready-to-use formulation to the patient. Serum eye drops should be included in the modern armamentarium against keratoconjunctivitis sicca, and, hopefully, their eventual widespread application will result in coverage by most if not all insurance funds. The implementation described contributes to the hopeful establishment of a standardized protocol and provides a potentially benefit of a low-cost, applicable treatment of the ocular epithelium without side effects.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2015
Pg. 252-260
Nov/Dec 2009
Pg. 506-515
Jul/Aug 2022
Pg. 336-341
Nov/Dec 2009
Pg. 540-543
Sep/Oct 2014
Pg. 370-377
Sep/Oct 2014
Pg. 418-426
Sep/Oct 2019
Pg. 418-421
Jul/Aug 2017
Pg. 282-289
Author(s): Choo Winnie
Jan/Feb 2001
Pg. 52-54
Author(s): Ford Gina, Garcia Lea
Sep/Oct 2004
Pg. 359-367
Author(s): Davidson Gigi S
Jul/Aug 2017
Pg. 319
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 419-423
Author(s): Tan Robert S
Sep/Oct 2000
Pg. 376
Author(s): Allen Loyd V Jr
Jul/Aug 2011
Pg. 290-300
May/Jun 2004
Pg. 169-172
Author(s): Davidson Gigi S
Jul/Aug 2004
Pg. 277-283
Author(s): Davidson Gigi S
Jul/Aug 1997
Pg. 253
Author(s): Allen Loyd V Jr
Jan/Feb 2010
Pg. 70
Author(s): Allen Loyd V Jr
May/Jun 2012
Pg. 190-195
Author(s): McElhiney Linda F
Sep/Oct 2020
Pg. 358-364